Background and objective: Dose-finding, aiming at finding the maximum tolerated dose, and pharmacokinetics studies are the first in human studies in the development process of a new pharmacological treatment. In the literature, to date only few attempts have been made to combine pharmacokinetics and dose-finding and to our knowledge no software implementation is generally available. In previous papers, we proposed several Bayesian adaptive pharmacokinetics-based dose-finding designs in small populations. The objective of this work is to implement these dose-finding methods in an R package, called dfpk .
Introduction
Dose-finding studies and pharmacokinetics (PK) are carried out at the first phases of clinical evaluation of a new drug in humans. Drug safety is evaluated in the dose-finding study, which aims at identifying the maximum tolerated dose (MTD) [1] . Meanwhile, the PK data collected during such study provides the description of the dose-concentration relationships [2] . Nevertheless, these two approaches are often conducted and reported independently in different sections in publications reporting trial results [3] . Identifying the right dose or set of doses at an early stage is crucial: selecting too toxic doses can result in patient overdosing, while selecting an inefficient dose increases the likelihood that the drug will be found to be ineffective in subsequent clinical evaluation [4] . Particularly in the case of small populations, such as rare diseases or paediatrics, it should be useful to take into account all the infor- mation collected during the trial, and to try to utilize the PK measurements within the dose-finding design. Only few attempts have been described in the literature so far and, usually, the methods were built for a very specific situation [5] [6] [7] [8] . Moreover, no software implementations are publicly available.
In this article we present the new R package dfpk (short for dose-finding Pharmacokinetics), which provides the Bayesian adaptive PK-based dose-finding designs in small populations proposed by Ursino et al. [8] through the freely available R software [9] . The six methods detailed in [8] have been implemented in dfpk . For each of them, two functions are provided: (i) a function to determine the next recommended dose (during the trial) or the recommended MTD (at the end of the trial) and (ii) a function to run simulations of phase I studies to design a new trial. Interactive graphical representations of the dose-concentration curve, of the dose allocation process in the trial and of the dose-toxicity response are also provided by the package.
The paper is organised as follows. Section 2 introduces the statistical methods proposed by Ursino et al. [8] , along with the description of the suggested scenarios to be simulated. Section 3 outlines the structure of the package and the main functions of the paper ( sim.data , nextDose and nsim ) with practical examples. Section 4 & 5 include conclusion, discussion and recommendations.
Computational methods
The present section briefly reviews the methods proposed by Ursino et al. [8] to perform dose-finding taking into account PK measurements. We then describe the scenarios simulated in [8] in order to evaluate the robustness of the method, which have been added as examples in the dfpk package.
Dose-finding methods
Let D = { d 1 , . . . , d k } be the set of K possible doses with d 1 < < d k and d [ i ] ∈ D be the dose administered to the i th subject ( i = 1 , . . . , n, where n denotes the sample size) and y i be a binary variable which takes value 1 if the i th subject shows a DLT (doselimiting toxicity) and 0 otherwise. Moreover, let z i be the logarithm of the area under the curve (AUC) of the concentrations of drug in blood plasma against time, for the i th patient.
All methods share the same fundamental idea for the doseescalation rule: the dose chosen for the next cohort enrolled is the one with probability of toxicity nearest to the target θ selected by the trial investigators. A no-skipping rule is given: if some doses have not yet been tested, the dose is chosen from D * ⊂ D , a subset of D which contains all the doses already evaluated and the first dose level immediately above. The final recommended MTD is given by the dose that would have been administered for the (n + 1) st subject enrolled in the trial. Finally, we added in all methods the same stopping rule: if the posterior probability of toxicity of the first dose is greater of a specified threshold, then no dose is suggested and the trial is stopped.
Each method is separated from the others. We adopted the convention of starting the subscription of β parameter from 0 for each method. Therefore, even if the parameters share the same names across models, they have different interpretations. In the following, we briefly describe how the probability of toxicity is estimated and computed in each method.
PKCOV
PKCOV is a modification of the method proposed by Piantadosi and Liu [5] who suggested to use the AUC as a covariate for p T , the probability of toxicity, through the logit link. Therefore, the dose-
where β = (β 1 , β 2 ) , β 0 is a constant selected through a sensitivity analysis or with prior information, z d k is the difference between the logarithm of population AUC at dose d k and z , the logarithm of AUC of the subject at the same dose. Independent uniform distributions are selected as prior distributions for β 1 and β 2 . In detail,
, where m 1 reflects the prior information on the parameter and the length of the domain of the distribution can go up to 10, and β 2 ∼ U (0, 5). Both β 0 and m 1 should be selected using prior information, such as from preclinical data, and sensitivity analysis should be done. The estimated probability of toxicity versus dose is obtained by inverting Eq. (1) , using β 1 = ˆ β 1 , the estimated parameter, and z d k = 0 .
PKLIM and PKCRM
PKLIM is a modification of the method proposed by Patterson et al. [6] and Whitehead et al. [10] . A normal PK-toxicity model is used:
where β = (β 0 , β 1 ) are the regression parameters, and ν is the standard deviation. A bivariate normal distribution and a beta distribution are chosen for β and ν, respectively, that is, β ∼ N(m , ν 2 (g )) and ν ∼ Beta (1, 1). Therefore, a hierarchical prior distribution is given to β, where m = (− log Cl pop , 1) and g should be chosen using prior information. For instance, Cl pop denotes the attended value of the clearance at population level, and g reflects the precision. The probability of toxicity of each dose is computed as
where L is a threshold set before starting the trial and the hat denotes the posterior means of the parameters. Since an assumption underlying the model is that DLTs are based on the AUC exceeding some threshold, the method could be applicable only when such a threshold is known. In order to avoid this problem, the PKCRM method was proposed, which is the combination of PKLIM and the CRM [11] using a power working model and normal prior on the parameter. In PKCRM the dose recommended for the next subject is the lowest of the doses recommended by the two methods. Note that although the same notation has been used for convenience, the parameters β 0 and β 1 are different in the different models.
PKLOGIT, PKPOP, PKTOX
PKLOGIT, inspired by Whitehead et al. [7] , combines two regressions to compute the probability of toxicity versus the dose. The first one is the same as Eq. (2) , that is z versus dose. In the second, z is used as a covariate in a logistic regression model for p T . This means that now the probability of toxicity is described in term of AUC and not any more in term of dose. Therefore, we have that
where β 2 and β 3 have independent uniform prior distributions, that is, β 2 ∼ U (0, m 2 ) and β 3 ∼ U (0, m 3 ), with m 2 ≥ m 3 , and values can be chosen using prior information. If no information is available, m 2 = 20 and m 3 = 10 are good starting values for a sensitivity analysis. The probability of toxicity associated with each dose is obtained by using the estimated parameters of each regression model in the following expected value formula: 
with represents the standard cumulative normal distribution. As in the previous models, independent uniform distributions are chosen as prior distributions for the parameters. The probability of toxicity versus dose is then computed in the same way of Eq. (5) using the probit regression inside the integral.
DTOX
DTOX follows the usual way of estimating p T versus dose directly without the PK measurements and is included to check the behaviour of this standard method. The dose-toxicity model is:
Independent uniform bivariate prior distribution is chosen for β in the same way of Eq. (4) .
Simulating data for trial design
The package implements several examples reproducing the scenarios proposed in Ursino et al. [8] to evaluate the method performance using simulated data. In these settings, toxicity is linked to a PK measure of exposure, namely to AUC, and we used a simulation setting similar to the one in [12] . A first order absorption, linear, one compartment PK model was used to simulate PK data. In this model, the concentration at time t after administration of a dose d k of the drug at time 0, can be written as a function of k a , the absorption rate constant for oral administration, CL, the clearance of elimination, and V, the volume of distribution, as follows:
Individual CL and V are sampled from log-normal distributions with mean CL pop (Lh −1 ) and V pop ( L ), respectively, and standard deviation ω CL = ω V , while k a is fixed in this study as limited information concerning the absorption phase was available in the original dataset to estimate its inter-individual variability. In order to link PK to the toxicity profile of patients, a sensitivity parameter α, coming from a log-normal distribution with mean equal to 1 and standard deviation ω α , and a threshold τ T are introduced.
We assumed that a patient incurs a dose limiting toxicity (DLT) if
Choosing the different parameters leads to several scenarios. The probability of toxicity is computed as:
R-functions
Package dfpk implements all the dose-finding methods described in Section 2 . In Fig. 1 , an overall explanation of the main functions in the dfpk package is given. The aim of the package is to assist the design of phase I clinical trials. During the trial, the patient data already accrued ("Trial data" in Fig. 1 A) can be used in the nextDose function in order to determine the next recommended dose, or the MTD at the end of trial. Plots are also available after the estimation process. When planning a new trial, datasets containing PK and toxicity measurements can be simulated directly by the user ("Simulated data") or through the sim.data function, and used in the nsim function (in Fig. 1 B. ), which will perform n simulated clinical trials. Also in this case, plots with graphical representations support the numeric results.
Bayesian parameter estimation is carried out using the rstan package while the ggplot2 package is used to create plots. Three S4 classes are implemented in the package, "dose" , "dosefinding" and "scen", in order to store the outputs of the main R functions nextDose , nsim and sim.data , respectively. The classes are detailed described in the Appendix B .
The package dfpk is available on the CRAN archive and can be easily installed on the fly through the URL https://cran.r-project. org/web/packages/dfpk . Once the package is installed, it can be loaded with the command:
In the remainder of this section, we present the R functions available in the package along with the required input parameters and examples. A more extensive demonstration and documentation can be accessed from the on-line user manual on the CRAN server by installing the package or directly within the R console. Table 1 Arguments for the functions nextDose and the dose-finding models.
model
The dose-finding model chosen between "pktox", "pkcov", "pkcrm", "pklogit", "pkpop" and "dtox". 
Dose-finding methods ( nextDose )
The nextDose function is used to perform parameter estimation at each step during a dose-finding trial. It gives the recommended dose to administer to the next cohort of patients, or the final estimated MTD if applied at the end of the trial. It can be used during an ongoing clinical trial or with a simulated dataset, as described later in the Section 3.2 .
The description of the input arguments used in the nextDose function are provided in Table 1 . The user has to choose the dosefinding method from the available set in the model parameter. Then, he/she should provide the parameters required by the selected method, as specified in Table 2 , while the others are set automatically to NULL. Any argument not specified by the user will be set to the corresponding default choice [8] . The number of chains and iterations for the Bayesian algorithm can be changed using the appropriate rstan options.
Demonstration
(A) PKTOX model In the following example, we supposed that a clinical trial is still ongoing and 15 patients have been enrolled so far.
For this case, PKTOX was selected as the dose-finding model. The nextDose function requires the following input arguments: the panel of doses of the drug, the target toxicity probability, θ and the options for the Stan model as a list, containing the number of chains, the number of iterations and the warm-up iterations.
Other necessary input arguments are the vector of dose levels assigned to the patients (as integer vector), that is denoted by x , the AUCs values and the vector of toxicity outcomes (0/1 are accepted), denoted as y , for each enrolled patient.
The user can change the prior distribution parameter of the toxicity-AUC regression by adding the parameter betapriors . If it is not specified, the value suggested by Ursino et al. [8] are used by default. The default choices of betapriors for PKTOX model are the following:
where Cl pop is the population clearance and the default choices are Cl pop = 10 , g = 10 0 0 0 , beta2mean = 20 and beta3mean = 10. Details about the default choices of all the dose-finding models are available in the user-manual on the CRAN.
These arguments are used in the nextDose function depending on the chosen model, PKTOX, using the following syntax:
omitting all default parameters. The results are stored in a "dose" object. The output below reports part of the results displayed, that is the number of patients who are currently enrolled, the selected dose-finding model, and the observed dose levels of the drug:
According to these results, the next recommended dose level is 5, which would be the dose for the next cohort of patients given the data. The estimated toxicity probabilities and model parameters are also shown:
The package also provides a graphical representation of the results. For example, using the generic function plot() on a "dose" object, we can select if we want to present graphically: (1) the dose allocation of the currently enrolled patients during the trial or (2) the posterior distributions of the probability of toxicity at each dose presenting the estimation along with the lines of the 95% credible intervals (CI), as below: In this section a second illustration is shown using the PKCRM dose-finding method in the function nextDose . In this way, we can highlight the differences in the required inputs/outputs. In this case, in addition to the input arguments that are used in the PKTOX Fig. 2. (A) Plot of the data for the first 15 patients in the study and, (B) the plot of the posterior distributions given this data of the probability of toxicity at each dose according to the PKTOX method (including the mean estimation along with the 95% CI). method (i.e. y, AUCs, doses, x, theta, options), the PKCRM method requires the skeleton of CRM ( p0 ) and the AUC threshold ( L ), which must be set before starting the trial. In this example we use:
After setting all the required arguments for the chosen PKCRM model, we call the nextDose function as following:
The resulting object displays as follows :
3.2.
Generate data (sim.data)
The sim.data function generates and stores PK and toxicity data in order to be used for simulation according to the model described in Section 2.2 . The initial step consists in generating the patients' responses at all doses for each trial. The function sim.data takes the trial's settings and returns a list of data including the subject's PK parameters along with the simulated toxicity observations. In particular, it starts by drawing subject's PK parameters ( k α , CL and V ) from the population distributions defined by the population mean ( PKparameters ) and the inter-individual variability (IIV) for the clearance and the volume of distribution ( omegaIIV ). Then, for each dose level ( doses ), we computed the desired probability of toxicity ( preal ), and for all patients ( N ) and simulated data ( TR ), it computes the concentration measurements at the specified time points ( timeSampling ). In addition, we add a proportional error drawn from a normal distribution with zero mean and a standard deviation sigma . According to eq. ( 9 ), the function computes the toxicity values for each dose level using the threshold limitTox and the patient's sensitivity parameter omegaAlpha . Finally, a default value of the random number generator ( seed ) is set at 190591.
The results are stored in a list of "scen" objects, which consists of PKparameters , nPK , the length of the time points, timeSampling , idtr , N , doses , preal , limitTox , omegaIIV , omegaAlpha , concentration , the concentration computed at the PK population values, concPred , the concentration values with proportional errors for each patient at each dose, tox , tab , a summary matrix, used in the simulation function, containing the sampling time points at the first row followed by concPred , parameters , the simulated PK parameters of each patient, alphaAUC , the αAUCs. Since we are using S4 classes, the user can easily create his/her own datasets. For example, he/she can create a new object for each simulated trial, named UserData , using the command new in the following way and then add it in a list, along with the other simulated datasets. A more expanded description of the "scen" class and objects can be accessed from Appendix B 2.
Demonstration
The following illustration shows how to generate the datasets of the first scenario described by Ursino et al. [8] . In this example, we set the number of trials to 10 (i.e. TR = 10), the threshold of toxicity value to 10.96, the dose levels to (12.6, 34.655, 44.69, 60.807, 83.689 and 100.371 mg) which are used to obtain the true probabilities of toxicity, 48 evenly spaced sampling time points between 0 and 48 h, a sample size of 30 and k a = 2 , CL = 10 and V = 100 as illustrated below:
Each trial's result is stored in a list of the R "scen" object, gen.scen , which regroups the subject's PK parameters, the concentration measurements for all patients and the simulated toxicities values at each dose level. Here, we provide some sim.data results for the first trial: Based on the above AUC with the sensitivity parameter values and the chosen toxicity threshold τ T = 10 . 96 , we observe for all patients (one row = one patient) in the second trial, the toxicity outcomes at each dose level (one dose = one column) as follows: In this example, we used α = 1 for all patients, but the user can simulate α from a log-normal distribution with mean = 1 and standard deviation ω α . Selecting ω α = 0 implies α = 1 as in this example.
Once again, providing the selected list of the generated "scen" object to the generic plot function plot , the user obtains a plot of the drug's concentration in the plasma against the time t . Under the same settings and outputs as above, the plot is implemented as follows: Fig. 3 presents the PK concentration curves, described in Section 2 , with the PK parameters k α = 2 h −1 , CL = 10 Lh −1 and V = 100 L for the 6 doses (12.6, 34.65, 44.69, 60.8, 83.69 and 100.37 mg).
Dose-finding simulation ( nsim )
The function nsim simulates a single or n prospective clinical trials. In the simulated trial, the dose is escalated stepwise cohort by cohort until the first toxicity response is observed and then the chosen dose-finding method design is applied (two-stage design) as suggested in Ursino et al. [8] .
In addition to the input arguments of nextDose , the nsim function has the following additional arguments: (i) N , the total sample size per trial, (ii) cohort , the cohort size, (iii) TR , the total number of trials to be simulated, (iv) simulatedData , a list for each trial containing previous simulated datasets as in 3.2.1 , (v) icon , a vector containing the index of real blood sampling that enables the user to use all concentration points, previously simulated, or only a subset of them and (f) AUCmethod , a string number specifying the estimation method for AUC; valid choices are 1 for a "compartmental method" (see [8] for details) and 2 for non-compartmental method (defaults to 2). The estimated AUC for each patient is computed inside the function nsim , using only the concentration samples selected by icon . By default, all simulated samples are used. Similarly to the nextDose function, the user needs to choose one of the dose-finding models which are available in the package.
Demonstration
As an example, 10 trials (i.e. TR = 10) were simulated with 30 patients (i.e. N = 30) per trial, using the function nsim . At the beginning, the simulatedData is defined (in this case, we use the simulated data gen.scen generated in the Section 3.2.1 ), representing the true toxicity probabilities of each trial, where six dose levels are considered. The dose levels should be entered in a vector, as follows:
The target toxicity probability theta is set to 0.2, meaning that the MTD is defined as the dose for which at most 20% of dose limiting toxicity (DLT) responses occur. For this example, the PKTOX method is selected and the 95% CI of the probability of toxicity at each dose is chosen to be estimated and included in the results since the input argument CI is set to TRUE . Since our simulation uses Stan models, we also need to specify the model's options, as a list, containing the number of chains, how many iterations each chain will use and the number of warm-up iterations. The default choice is:
After setting the index of real blood sampling (i.e. icon ) and entering the corresponding model's input parameters, we call the nsim function as following:
The result is saved in the R object, named simResult , of a S4 class "dosefinding". The output can be divided in three parts. The first part shows a data summary of the chosen dose-finding model (PKTOX in this case), the second part the Stan options and finally the dose-finding results including the percentage of the dose-allocation and the percentage of the MTD selection. The generated output is as follows:
Based on the above example, the next recommended dose level is 4 mg with a percentage of MTD selection equals to 60%.
The MTD, toxicity responses as well as the dose escalation for each trial can be obtained as follows:
The generic function plot() can be used in order to illustrate the dose escalation during the trial or the dose-toxicity response for each dose level. The main input argument is a "dosefinding" object. The simulation output can be shown graphically with the command:
where TR represents the number of trial (defaults to TR = 1) for which we want to plot the graph, CI indicates if the simulation's results include the estimated 95% of the probability of toxicity or not (defaults to CI = TRUE ) and ask represents the plot selection index (defaults to ask = TRUE) showing a selection menu as above: the user should enter 1 to see the dose escalation allocation of the selected trial, 2 to create a boxplot of the sampling distribution of the probability of toxicity at each dose in the end of the trial over the total number of trials, and 3 to plot the final posterior distributions of the probability of toxicity at each dose (the plot includes the estimation along with the lines of the 95% CI for the selected trial). 0 is the command to exit and 2 is the default choice for the input ask . Note that, if the simulation's results don't include the 95% CI of probability of toxicity then the selection menu contains only the first two choices. Fig. 4 (A) shows the dose allocation plot based on our example, where the non-toxicity response is represented as a circle and the toxicity response as a cross. In addition, Fig. 4 (B) and 4 (C) present the output plot choosing, in the menu, 2 and 3, respectively. In Fig. 4 (C) , the 95% CI and prior probabilities of toxicity are represented as dotted and dashed lines, respectively. The red dot-dash line in the last two Figures represents the toxicity threshold which is used for the selection of the MTD.
Note that, since the Bayesian models are implemented in Stan, running simulations can take very long time. Moreover, simulations including the estimation of the 95% credible intervals (CI) for probability of toxicity at each dose level (i.e. CI = TRUE ), can take more time than excluding them (i.e. CI = FALSE ). In this case, to run the 10 trials including the 95% CI of probability of toxicity, about 30 min are needed on a single portable computer with an Intel Core i5. Instead, to simulate only the MTD under the same settings, without estimating the 95% CI, about 18 min are required on the same computer. A more expanded comparison of the nsim function and for 1,0 0 0 simulated trials, which is often used for the simulation studies in the literature of dose-finding methods, are shown in Appendix A . However, we suggest to run simulations on a dedicated server.
Conclusion
The dfpk package implements novel methods for dose-finding phase I clinical trials incorporating PK in the dose-toxicity relationships [8] . In this package, each method can be used during a prospective adaptive trial, where the dose for the next cohort of patients depends on the outcomes of the previous cohorts, in order to estimate the recommended dose for further clinical trials. It can also be used to perform simulations before the beginning of trial in order to study the robustness of the method to the different parameters setting choices. Running simulations is also useful to calibrate some parameters, but it takes time, therefore we suggest to run simulations on a dedicated server.
The package is user-friendly and several flexible inputs are allowed: for instance the user can generate by her/himself scenarios (simulated datasets) and pass them on to the function nsim , or change the hyper-prior parameters of the prior distributions used in the Bayesian regression. The package will also be updated according user suggestions and needs.
Discussion
Designing early phase clinical trials is of crucial importance, since all future steps in the clinical development or failures depend on these first results. Statistical computer programs, such as R , facilitate design and the checking of performance through simulations. An example of existing R packages can be found in [13] . However, to the best of our knowledge, there are no other software packages available that implement a formal integration of dose-finding and pharmacokinetics. Our R package can support interdisciplinary trial teams in implementing innovative dose-finding design using PK information in phase I studies.
Ursino et al. [8] compared a number of dose-finding methods under several scenarios, in order to verify their behaviour and characteristics. The PKCRM method behaves as the CRM alone when the L is very high. On the other hand, it gives the same probability of correct MTD selection (as the CRM) while reducing the probability of overdosing, when L is appropriately chosen. Therefore, this design is recommended when in preclinical phases nonmonitorable toxicity has been observed or in some pediatric studies, when L can be easily set from a literature review. The PKLOGIT and PKTOX methods are recommended when more precise doseresponse curve estimation is required. Compared to the CRM these methods are able to better estimate the probability of toxicity associated with each dose along with accurate MTD selection. In this way, a richer knowledge can be transmitted to subsequent phases of clinical development. The other methods have similar behaviour to any dose-toxicity regression, and can be used for comparisons in simulations.
The choice of the prior distributions is crucial. In this package, we set as default the prior distributions suggested in [8] . These prior hyperparameters were chosen after sensitivity analysis to give good performance in most cases. However, we suggest setting the prior hyperparamenters using preclinical information or other external pertinent information if this is available.
Simulations based on Bayesian methods can be very tedious and time consuming. Therefore, for 1,0 0 0 simulated trials, we suggest to use a dedicated server. Moreover, running in parallel all the scenarios and not sequentially can also reduce the time of the simulations. Table A .1 shows the estimated times for conducting the simulations of 10 and 1 ,0 0 0 trials, excluding the 95% credible intervals, for the methods PKTOX and PKCRM under several settings (i.e. the number of chains and iterations for the Bayesian algorithm). 
Appendix B. S4 classes
One of the big advantages of dfpk package is its flexible framework based on the S4 classes and methods structure. S4 classes have allowed us to construct rich and complicated data representations that nevertheless seem simple to the end user. The class is the abstract definition, while every time we actually use it to store the results for a given data set, we create an object of the class.
Three S4 classes are available, the dose-class , the scen-class and the dosefinding-class , in order to store, show or plot the corresponding results of the main R functions nextDose , sim.data and nsim , respectively. You can click on the corresponding help pages as background information for the next steps. The estimated mean probabilities of toxicity. pstimQ1
The 1st quartile of estimated probability of toxicity. pstimQ3
The 3rd quartile of estimated probability of toxicity. parameters
The Stan model's estimated parameters. model A character string to specify the selected dose-finding model used in the method.
In this section, a briefly description of the accessible classes is shown.
dose-class
The dose-class is created to store and present the next recommended dose level in an ongoing trial through the R function nextDose . We can look in detail at the structure of the class as follows:
where, ClassNewDose is a union of classes "numeric", "logical" and "NULL". Accordingly to the structure, the dose class consists of 13 slots (i.e. arguments) which each one has a specific type. Table B .1 gives a brief definition of each corresponding slots in the dose class.
An object that comes from the dose-class must contain all the above slots. The slots are accessed using @, just as components of a list that are accessed using $. Here, an illustration of how to access the slots of an object is given.
We suppose that nextD is an object of the dose class. For example, the slots model and y can be obtained as follows:
where, PKTOX was the selected dose-finding model and the vector (0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0) was the toxicity outcome for each patient that are used in the function nextDose .
Once the classes are defined, we probably want to perform some computations on objects. In most cases we do not care how the object is stored internally, the computer should decide how to perform the tasks. The S4 way of reaching this goal is to use generic functions and method dispatch. Based on our above example, we hypothesised that we stored the output of the function nextDose in the object nextD . To present the results we can use either the method show or print as follows:
Both methods give a nice and simple presentation of the outcome that is stored in the object nextD . In any case where user wants to change how the results are presented, she/he can easily do it by setting her/his own show or print method in the class dose . Similarly, a plot generic function is defined for this class and can be easily accessed through the command:
2. scen-class A scen is a S4 class to save and show a dataset simulated by the function sim.data . We can look in detail at the structure of the class scen as follows:
Thanks to S4 classes, the user can easily create his/her own datasets. For example, he/she can create a new object for each simulated trial, named UserData, and store it in a scen-class by a similar way using the command new in the following way:
and then add it in a list, along with the other simulated datasets.
A detailed definition of each slot is presented in the Table B. 2 . Once again, user can access to the slots and apply the generic functions and methods in this class by exactly the same way as in dose-class . Assume that we run 10 (i.e. TR = 10) simulated datasets using the function sim.data and simulatedData is a scen object then:
dosefinding-class
Lastly, a third S4 class is available in the package dfpk, called dosefinding , which is created to store all the dose-finding results that are simulated through the R function nsim . The total number of trials to be simulated. preal
The prior toxicity probabilities. pstim
The estimated mean probabilities of toxicity. pstimQ1
The 1st quartile of the estimated probability of toxicity. pstimQ3
The 3rd quartile of the estimated probability of toxicity. model A character string to specify the selected dose-finding model used in the method. seed
The seed of the random number generator that is used at the beginning of each trial.
It's structure is given below:
where, 21 different slots are available. Table B. 3 defines all the possible slots.
Identically with the dose and scen S4 classes, the slots can picked using the @ "operator" and the generic functions and methods can be applied in the same way.
